Tieton Capital Management’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.95M | Buy |
2,029,155
+384,062
| +23% | +$2.07M | 3% | 19 |
|
|
2025
Q4 | $10.5M | Sell |
1,645,093
-1,825
| -0.1% | -$12.7K | 3.58% | 11 |
|
|
2025
Q3 | $15.4M | Buy |
1,646,918
+65,608
| +4% | +$662K | 5.33% | 3 |
|
|
2025
Q2 | $22.8M | Sell |
1,581,310
-404,730
| -20% | -$4M | 8.91% | 1 |
|
|
2025
Q1 | $13.7M | Sell |
1,986,040
-602,574
| -23% | -$3.79M | 6.26% | 3 |
|
|
2024
Q4 | $13.7M | Sell |
2,588,614
-367,506
| -12% | -$2.01M | 5.52% | 3 |
|
|
2024
Q3 | $10.8M | Sell |
2,956,120
-11,940
| -0.4% | -$37.6K | 5.59% | 4 |
|
|
2024
Q2 | $8.1M | Sell |
2,968,060
-53,815
| -2% | -$180K | 4.5% | 6 |
|
|
2024
Q1 | $10.5M | Buy |
3,021,875
+108,200
| +4% | +$200K | 5.51% | 4 |
|
|
2023
Q4 | $4.17M | Buy |
2,913,675
+461,692
| +19% | +$643K | 2.35% | 18 |
|
|
2023
Q3 | $3.58M | Sell |
2,451,983
-118,165
| -5% | -$185K | 2.26% | 19 |
|
|
2023
Q2 | $4.04M | Buy |
2,570,148
+21,438
| +0.8% | +$32K | 2.59% | 17 |
|
|
2023
Q1 | $3.9M | Sell |
2,548,710
-196,314
| -7% | -$349K | 2.78% | 19 |
|
|
2022
Q4 | $4.61M | Buy |
2,745,024
+469,429
| +21% | +$744K | 3.05% | 17 |
|
|
2022
Q3 | $2.8M | Sell |
2,275,595
-9,420
| -0.4% | -$15.2K | 1.97% | 25 |
|
|
2022
Q2 | $3.82M | Buy |
2,285,015
+856,273
| +60% | +$1.67M | 2.64% | 18 |
|
|
2022
Q1 | $3.52M | Buy |
1,428,742
+1,012,016
| +243% | +$2.77M | 1.94% | 23 |
|
|
2021
Q4 | $1.56M | Buy |
416,726
+115,792
| +38% | +$625K | 0.87% | 31 |
|
|
2021
Q3 | $1.89M | Sell |
300,934
-8,835
| -3% | -$72.8K | 1.03% | 29 |
|
|
2021
Q2 | $3.05M | Sell |
309,769
-1,065
| -0.3% | -$9.29K | 1.63% | 27 |
|
|
2021
Q1 | $2.9M | Sell |
310,834
-842,270
| -73% | -$6.68M | 1.67% | 28 |
|
|
2020
Q4 | $5.54M | Sell |
1,153,104
-36,800
| -3% | -$179K | 4.05% | 9 |
|
|
2020
Q3 | $4.77M | Buy |
1,189,904
+173,124
| +17% | +$835K | 4.72% | 5 |
|
|
2020
Q2 | $4.67M | Sell |
1,016,780
-448,762
| -31% | -$2.01M | 5.84% | 2 |
|
|
2020
Q1 | $4.78M | Sell |
1,465,542
-81,585
| -5% | -$313K | 7.68% | 1 |
|
|
2019
Q4 | $6.67M | Buy |
1,547,127
+125,247
| +9% | +$445K | 5.33% | 6 |
|
|
2019
Q3 | $5.59M | Buy |
1,421,880
+99,310
| +8% | +$423K | 4.77% | 6 |
|
|
2019
Q2 | $6.15M | Buy |
1,322,570
+64,680
| +5% | +$276K | 5.38% | 2 |
|
|
2019
Q1 | $5.27M | Buy |
1,257,890
+165,425
| +15% | +$596K | 4.69% | 5 |
|
|
2018
Q4 | $3.75M | Buy |
1,092,465
+11,220
| +1% | +$39K | 4.21% | 8 |
|
|
2018
Q3 | $4.64M | Buy |
1,081,245
+172,394
| +19% | +$741K | 3.7% | 13 |
|
|
2018
Q2 | $3.37M | Buy |
908,851
+348,131
| +62% | +$1.32M | 2.61% | 23 |
|
|
2018
Q1 | $2.35M | Sell |
560,720
-7,680
| -1% | -$40.2K | 2.16% | 24 |
|
|
2017
Q4 | $3.34M | Sell |
568,400
-22,302
| -4% | -$120K | 2.87% | 20 |
|
|
2017
Q3 | $2.54M | Sell |
590,702
-25,918
| -4% | -$94.8K | 2.18% | 21 |
|
|
2017
Q2 | $2.35M | Sell |
616,620
-72,115
| -10% | -$228K | 2.17% | 21 |
|
|
2017
Q1 | $1.85M | Buy |
+688,735
| New | +$1.95M | 1.61% | 26 |
|
Other funds holding NAGE
SW
VCM
VPM
Tieton Capital Management's NAGE Position: Q1 2026 in Review
Tieton Capital Management increased its Niagen Bioscience (NAGE) stake by 23% in Q1 2026, buying an estimated $2.07M and bringing the position to 2,029,155 shares worth $8.95M. The position accounts for 3% of the portfolio, ranked #19.
Tieton Capital Management first reported a position in NAGE in Q1 2017 and has held it in 37 quarters since. The position peaked at $22.8M in Q2 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.
- Tieton Capital Management held 2,029,155 shares of Niagen Bioscience worth $8.95M as of Q1 2026.
- Tieton Capital Management bought 384,062 Niagen Bioscience shares in Q1 2026, an estimated $2.07M.
- Niagen Bioscience made up 3% of Tieton Capital Management's portfolio in Q1 2026, its #19 holding.
- Tieton Capital Management first reported a position in Niagen Bioscience in Q1 2017 and has held it in 37 quarters since.
- Tieton Capital Management's Niagen Bioscience position peaked at $22.8M in Q2 2025.
- 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.
Based on Tieton Capital Management's 13F filing for Q1 2026, filed 8 May 2026.